ERGO.L Regulatory News (ERGO)

 PRESS RELEASE

Mark Enyedy Appointed to Board as Non-Executive Director

Guildford, UK - 10 May 2021: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, today announces that Mark Enyedy will join the Board as a Non-Executive Director with effect from 10 June 2021. 

Mr Enyedy brings more than 25 years of senior leadership experience in the biopharmaceutical sector, including executive management, corporate development and legal roles, across multiple therapeutic areas with a focus on rare diseases and oncology. He is currently President and Chief Executive Officer and a Director of ImmunoGen, Inc., a publicly-traded biotechnology company, where he oversees strategy and operations. He is also a member of the Board of Directors of the Biotechnology Innovation Organization (BIO), the world's largest advocacy organisation representing the biotechnology industry in the US and globally.

Prior to ImmunoGen, Mr Enyedy served in various executive capacities at Shire plc, including as Executive Vice President and Head of Corporate Development, a role in which he negotiated and integrated the multi-billion dollar acquisitions of NPS Pharmaceuticals and Dyax Corp. and oversaw the $32 billion combination with Baxalta, Inc. Mr Enyedy was also previously President of the Transplant, Oncology and Multiple Sclerosis division at Genzyme Corporation, and under his leadership the division achieved revenue growth from under $10 million to more than $675 million in just seven years. He began his career as an attorney at Palmer & Dodge, a Boston-based law firm where his practice focused on representing biopharmaceutical, high technology, and energy companies in M&A, licensing, and financing transactions.

Mr Enyedy also serves on the Boards of Directors of The American Cancer Society of Eastern New England and LogicBio Therapeutics, Inc. (Nasdaq: LOGC). He holds a J.D. from Harvard Law School and a B.S. from Northeastern University.

Dr Miroslav Reljanović, Executive Chairman of Ergomed, commented: "Mark has extensive corporate development experience in the US, UK and globally from his time in senior public company strategic leadership roles. Throughout his career he has achieved an outstanding and consistent track record of building new businesses through organic growth, corporate development, and M&A. Over the past 20 years, he has been strongly focused on rare disease and oncology, and brings to Ergomed exceptional levels of expertise, insight and connections which will support our continuing drive to strengthen our global leadership in these sectors. Mark is an outstanding addition to Ergomed, and on behalf of the Board, I am delighted to warmly welcome him to his new position."

Mark Enyedy said: "Ergomed is at an exciting stage in its development. The Company's success in recent years reflects the continued strong execution of both its organic and inorganic growth strategy, creating leadership positions in its chosen high-growth specialist markets. I look forward to working closely with the management team to develop innovative strategies that will accelerate the company's continued international growth."

Mr Mark Joseph Enyedy, aged 57, holds or has held directorships in the five years preceding his appointment at Ergomed as follows:

ENDS

Enquiries:

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.